Catalyst Dossier · compiled by CeliA 🧫

PharmaMar, S.A. (PHM.MC)

Operative Builders · market cap $26.2B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

PharmaMar, S.A. (PHM.MC) is a Spanish biotech with an unusually sprawling pipeline spanning oncology, rare diseases, CNS, infectious disease, and inflammation — including its marine-derived compounds lurbinectedin and plitidepsin alongside numerous partnered or in-licensed assets. The company carries a reported market cap of approximately $26.2B with consensus analyst coverage tilting toward buy (9 ratings, mean target ~$105). Key financial data including cash, runway, and dilution are unavailable from the provided facts, which materially limits balance-sheet visibility.

The catalyst path

2026-07-15 (est.)Phase 2 · APHD-012imp 7/10
2026-10-31 (est.)Phase 2 · QHRD106 Injection (Low-dose group)imp 7/10
2026-12-15 (est.)Phase 2 · NS-229imp 7/10
2026-12-15 (est.)Phase 2 · STP938imp 7/10
2026-12-30 (est.)Phase 3 · ASKB589imp 9/10
2026-12-30 (est.)Phase 2 · HEC169096imp 7/10
2027-03-15 (est.)Phase 2 · ICP-488 Tabletsimp 7/10
2027-03-15 (est.)Phase 2 · ICP-322imp 7/10

Pipeline

Asset	Phase	Indication
PerioChip ®	Phase 3	Generalized Adult Periodontitis
PHP-201 0.25% ophthalmic solution	Phase 2	Normal Tension Glaucoma
CP-4055	Phase 2	Malignant Melanoma
LAT8881	Phase 2	Acute Migraine
C21	Phase 2	Idiopathic Pulmonary Fibrosis
E6011	Phase 2	Crohn's Disease
acalabrutinib	Phase 2	Non Hodgkin Lymphoma
Naloxone SR 5 mg capsules	Phase 2	Chronic Pain
LEO 138559	Phase 2	Atopic Dermatitis
Levocetirizine	Phase 3	Dermatitis, Atopic
V120083	Phase 2	Osteo Arthritis Knee
ICP-488 Tablets	Phase 2	Cutaneous Lupus Erythematosus (CLE)
TSX-002	Phase 2	Hypogonadism
OC-01 (varenicline) nasal spray	Phase 2	Dry Eye Disease
VNX001	Phase 2	Interstitial Cystitis
NS-065/NCNP-01	Phase 2	Duchenne Muscular Dystrophy
JTT-851	Phase 2	Type 2 Diabetes Mellitus
Relugolix Combination Tablet	Phase 3	Uterine Fibroids
Ingenol mebutate gel 0.05 %	Phase 3	Actinic Keratosis
ICP-192	Phase 2	Intrahepatic Cholangiocarcinoma (ICC)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PHM.MC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.